TMDA/DMC/MRE/F/016 Rev #:02

THE UNITED REPUBLIC OF TANZANIA

**MINISTRY OF HEALTH** 

TANZANIA MEDICINES AND MEDICAL DEVICES AUTHORITY

PUBLIC ASSESSMENT REPORT FOR XARELTO (RIVAROXABAN 2.5 MG) FILM ¢OATED TABLETS

> Version number 1.0 05 January, 2022

TMDA Headquarters, Plot No. 56/1, Block E, Kisasa B Centre, Swaswa Road, P. O. Box 1253, Dodoma – Tanzania, Telephone: +255 (26) 2961989/2061990/+255 (22) 2450512/2450751/2452108, Email: info@tmda.og.tz, Website: www.tmda.go.tz

Toll free: 0800110084

Effective date: 03/10/2022

## 1. Introduction

Xarelto 2.5 is an innovator medicine. Rivaroxaban is a highly selective direct factor Xa inhibitor with oral bioavailability. Inhibition of factor Xa interrupts the intrinsic and extrinsic pathway of the blood coagulation cascade, inhibiting both thrombin formation and development of thrombi. Rivaroxaban does not inhibit thrombin (activated factor II) and no effects on platelets have been demonstrate. Xarelto is approved in Tanzania for use only in adult patients.

# 1.1.Product details

1								
Registration number	TAN 21 H 0487							
Brand name	Xarelto 2.5							
Generic name, strength, and form	Each film-coated tablet contains 2.5 mg rivaroxaban							
ATC classification	ATC Code- B01AF01–Direct factor Xa Inhibitors							
Distribution category	РОМ							
Country of origin	Germany							
Associated product	Xarelto 10, Xarelto 15, Xarelto 20							
Marketing Authorization Holder	E-mail:ra.middleafrica@bayer.com ;							
Local Technical Representative	JD Pharmacy Limited, P.O. Box 1899, Dar es Salaam.							

# 1.2.Assessment procedure

The application for registration of Xarelto was submitted on 25 June 2020. The product underwent abridge assessment. Assessment was completed in 2 (two) rounds of evaluation and the product was registered on 26 November 2021.

# 1.3.Information for users

Visual description of the finished product	Light yellow, round biconvex tablets (6 mm diameter radius, 9 mm radius of curvature) marked with the BAYER-cross on one side and "2.5" and a triangle on the other side							
Primary packing material	Polypropylene/Alu Blister							
Secondary packing materials	A printed carton box							
Shelf-life and storage condition	36 months, Do not store above 30°C							
Route of administration	Oral							

Therapeutic indications	Xarelto, co-administered with acetylsalicylic acid (ASA) alone or with ASA plus clopidogrel or ticlopidine, is indicated for the prevention of atherothromboticevents in adult patients after an acute coronarysyndrome (ACS) with elevated cardiac biomarkers.
	Xarelto, co-administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (CAD) or symptomatic peripheral artery disease (PAD) at high risk of ischemic events.

#### 2. Labelling and product information

# Summary of product characteristics

The SmPC included all the relevant information to ensure correct and safe use of the medicine by healthcare providers. The complete SmPC can be accessed <u>here</u>.

#### Package insert/leaflet

The package insert is confirmed to be derived from the SmPC and contains sufficient data for the end user. Since the product is POM, the package insert contains full prescribing information as per SmPC.

Container labels

The product label information is presented in English. Details in the secondary pack label include:

Brand name: Xarelto

Composition: Each film-coated tablet contains 2.5 mg Rivaroxaban

Pack size: 28 film-coated tablets

Manufacturing details: batch number, manufacturing date, and expiry date

Storage conditions: Do not store above 30°C

Manufacturer address: physical address of release site

Unique identifier: Not applicable

Special warnings/precautions or instructions for use: Contains lactose. See package insert for detailed directions for use and complete information on dosage

The details of the primary pack include:

Brand name and strength: Xarelto (2.5 mg)

Manufacturing details: batch number, manufacturing date and expiry date

Name of manufacturer: Bayer

The content of the primary and secondary labels was aligned to the requirements of the Part V of the Compendium: Guidelines on Format and Content of Product Labels for Medicinal products. The label contains sufficient information for proper identification of the medicine and post marketing follow up of the product.

Mock labels are appended as annex I.

# 3. Scientific discussion

# **Quality of Active Pharmaceutical Ingredients**

Information on the quality of the API was submitted in form of DMF.

## General Information


Rivaroxaban API is compendia in Ph.Eur. and BP.

Molecular formula: C<sub>19</sub>H<sub>18</sub>ClN<sub>3</sub>O<sub>5</sub>S

Chemical name:

5-Chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl) phenyl]-1,3-oxazolidin-5-yl} methyl)-2-thiophenecarboxamide

Structure:



# **General properties**

The active substance is a non-hygroscopic, crystalline white to yellowish solid, soluble in dimethylsulphoxide and insoluble in water. Rivaroxaban exhibits stereoisomerism due to the presence of one chiral centre. The S-isomer is the desired form. Enantiomeric purity is controlled routinely in the specifications.

Polymorphism has been observed for Rivaroxaban; Rivaroxaban crystallizes in three polymorphs;

thermodynamically stable form is used to manufacture the finished product. The same polymorphic form is manufactured by the API-DMF holder and it is routinely controlled in the active substance specification by XRPD.

Rivaroxaban is a class II substance in the BCS classification system. It has a low aqueous solubility, which is overcome by reducing the particle size with micronization. Appropriate limits have been included in the active substance specifications to monitor the particle size and size distribution.

#### Manufacture

Rivaroxaban API manufacturer is Bayer AG The manufacturing complies with GMP requirements as evidenced by the GMP certificate issued by the <state the issuing

authorities>. Rivaroxaban API is manufactured by chemical synthesis using conventional techniques. Sufficient controls of quality of materials and in-process checks were employed throughout the manufacturing process.

# **Specifications**

The API specifications were set as per Ph.Eur. and BP standards and ICHQ3A. The parameters monitored during quality control are: Color, identity (IR, UV, and HPLC, Raman spectroscopy), particle size (laser diffraction), enantiomeric purity (HPLC), appearance of solution color (Ph. Eur), heavy metals (Ph. Eur), palladium (Ph. Eur), residual solvent (GC), assay (HPLC), related impurities (HPLC), water content (KF), sulphated ash (Ph. Eur), and microbial purity (Ph. Eur. / USP / Ph. Jap). Compliance to these specifications were established via batch analysis data and stability studies.

#### Stability and container closure system

The re-test period of Rivaroxaban API is 36 months when packed in polypropylene foil bag 100  $\mu$ m PP colorless transparent (1030) packed in tight closed containers for mechanical protection with storage condition 'Do not store above 25°C'.

## **Quality of the Finished Pharmaceutical Product**

#### Formulation

Xarelto 2.5 is a light yellow, round, biconvex, film-coated tablet of a diameter of 6 mm and a radius of curvature of 9 mm. The tablet weight is 87.5 mg. The tablet markings are a triangle over "2.5" on one side and a Bayer cross on the other side.

Xarelto 2.5 contains the Rivaroxaban and other ingredients listed here after: Microcrystalline cellulose, Croscarmellose sodium, Lactose monohydrate, Hypromellose 2910, Sodium laurilsulphate, Magnesium stearate, Macrogol 3350, Hypromellose 2910, Titanium dioxide (E 171), Iron oxide yellow (E 172). The quantities of all ingredients are confirmed to be in line with the recommendations of Handbook of Pharmaceutical Excipients, 8<sup>th</sup> Edition in terms of function and quantities.

#### Manufacture

The finished product manufacturers are Bayer AG, Kaiser-Wilhelm-Allee, 51368 Leverkusen, Germany, Bayer HealthCare Manufacturing S.r.I. Via delle Groane, 126, 20024 Garbagnate Milanese, Italy, and Stegemann Lohnverpackung &Logistischer Service e.K. Up'n Nien Esch 14, 48268 Greven, Germany. The compliance of the sites to TMDA GMP standards was confirmed through <site inspection/desk-review> on <date of GMP compliance>.

#### **Specifications**

The FPP is compendia in BP. The manufacturer controls the quality of the finished product as per in-house standards and ICH requirements. The parameters monitored during quality control are: appearance, identification (TLC, NIR and HPLC), assay (HPLC), dissolution (HPLC), uniformity of dosage units (Ph. Eur), impurities (HPLC), and microbial purity (Ph. Eur). Compliance to the standard was established using batch analysis data and stability data.

## Stability and container closure system

Stability studies were conducted on a 3(three) batches of the finished product stored at  $30 \pm 2^{\circ}$ C & RH: 75 ± 5% RH for 36 months and 40± 2°C & RH: 75% ± 5% RH for 6 months. Based on the stability data presented, the approved shelf-life is 36 months when stored in Polypropylene/Alu blister with storage condition 'Do not store above 30°C'.

## Safety and efficacy information

The product underwent abridge assessment hence this section was not reviewed.

#### 4. Benefit-Risk Assessment and Conclusion

On basis of the data submitted, the current state of knowledge and compliance to Good Manufacturing Practice, the benefit of the product outweighs the risks associated with its use when used in accordance to the summary of product characteristics. Xarelto 2.5 is recommended for registration.

#### 5. Post-approval updates

#### Variation applications

Reference number	D a t submitted	е	Change requested	Recommendation	Granting date		

# Feedback from pharmacovigilance, post marketing surveillance and enforcement activities

Type of feedback	Impact	Response				

#### **Re-registration applications**

Application for renewal of registration was submitted on <DDMMYYYY>. The application was finalized in <number> rounds of evaluation. The product was confirmed to still be compliant to the standards of quality, safety and efficacy, hence registration was renewed on <DDMMYYYY>.

# PART 5: CHANGE HISTORY

Version number	Date	Description of update	Section(s) Modified	Approval date		

# Annex I: Mock up labels;

Primary pack label;

	LOT	87058646	,	LOT	87058646		LOT	87058646		LOT	87058646		LOT	87058646		LOT	87058646
Mon Lun.	ut per	Mon Lun.	Mon Lun.	-set of	Mon Lun.	Mon Lun.	ut per	Mon Lun.	Mon Lun.	-ind	Mon Lun.	Mon Lun.	-ind joint	Mon Lun.	Mon Lun.	ne jane	Mon Lun.
Tue Mar.	edby/Fiderig Lacon Mertagne	Tue Mar.	Tue Mar.	Manufactured by / Painiqu Baer AG 3381 Lowerkusen Gernary / Alertagne	Tue Mar.	Tue Mar.	ndby/Falanty Namen	Tue Mar.	Tue Mar.	Man factured by Frabriqu Bayer XG 3338 Loverhusen Gernary (Alleringno	Tue Mar.	Tue Mar.	od by / Fabriq kusen Jerragne	Tue Mar.	Tue Mar.	redby/Fabri okaon Menagoo	Tue Nar.
Wed Mer.	Manufactured by (Fel Bayer AG 3301 Loverhaen Genrany (Allemagne	Wed Mer.	Wed Mer.	Nendactur Bayer AG S1388 Lover Gennamy (A	Wed Mer.	Wed Mer.	Menufactu Bayer AG S1308 Leve Gennany fi	Wed Mer.	Wed Mer.	Nendactur Bayer AG 5 300 Lover Gernany (J)	Wed Mer.	Wed Mer.	Manfachurod by / Fal Bayer AG Basel Loverbuen Genrany (Allemagne	Wed Mer.	Wed Mer.	Nandacharol by Frai Bayer AG 3301 Loverhaen Gennary (Allen agno	Wed Mer.
Thu Jeu.		Thu Jeu.	Thu Jeu.		Thu Jeu.	Thu Jeu.		Thu Jeu.	Thu Jeu.		Thu Jeu.	Thu Jeu.	elets Birden	Thu Jeu.	Thu Jeu.	s mg Tablets to Comprise Macules coste	Thu Jeu.
Fri Ven.	5 mg Tab se Comprise oraté	Fri Ven.	Fri Ven.	25 mg Tablets take Comprise Naculas take conte	Fri Ven.	Fri Ven.	5 mg Tab se Acomprise orate	Fri Ven.	Fri Ven.	5 mg Tat is Comprue oraté	Fri Ven.	Fri Ven.	5 mg Tab as rCompine oraté	Fri Ven.	Fri Ven.	5 mg Tab se Kompine onde	Fri Ven.
Sat Sam	Xarelto* 25 mg Tablets Ph.comd teles Congriss Pecules Riversation Ord User Vela orde	Sat Sam.	Sat Sam.	Xarelto <sup>®</sup> 25 mg An coated tables fCon Riversation Oral Use / Vole orate	Sat Sam.	Sat Sam.	Xarelto" 25 mg Tablets Anced take Congress Recuke Reconstant Ord Use / Nete onde	Sat Sam.	Sat Sam.	Xarelto* 25 mg Tablets Fin count their former heruks Riversation Ont Use / Nee onte	Sat Sam.	Sat Sam.	Xarelto" 25 mg Tablet An Cost Vake Conprise R Rymoustern Ord Use / Vake ondé	Sat Sam	Sat Sam.	Xarelto <sup>®</sup> 2.5 n Fin Costol Tetats / Fivensisten Ord Use / Vote or	Sat Sam.
Sun Dim. a7058646	MFD EXP	Sun Dim.	Sun Dim. 87058646	MFD EXP	Sun Dim.	Sun Dim. 87058646	MFD EXP	Sun Dim.	Sun Dim. #7058646	MFD EXP	Sun Dim.	Sun Dim. 87058646	MFD EXP	Sun Dim.	Sun Dim. 87058646	MFD EXP	Sun Dim.
	LOT	87058646		LOT	87058646		LOT	87058646		LOT	87058646		LOT	87058646		LOT	87058646
Mon Lun.	and integra	Mon Lun.	Mon Lun.	Ni.	Mon Lun.	Mon Lun.	if thrital per	Mon Lun.	Mon Lun.	i.	Mon Lun.	Mon Lun.	ă.	Mon Lun.	Mon Lun.	li.	Mon Lun.
Tue Mar.	Mandactured by 1F dari Bayar AG 5008 Lawkusan Gerrany ( Alemagne	Tue Mar.	Tue Mar.	edby (Fahiqué Nusen Naragne	Tue Mar.	Tue Mar.	ndby (Fånd Nuen Menagre	Tue Mar.	Tue Mar.	edby if daripué Autom Menagre	Tue Mar.	Tue Mar.	ndby (Fabrique) Nusen Nemgre	Tue Mar.	Tue Mar.	edby (Fabriqué Nuem Menagre	Tue Mar.
Wed Mer.	Nandach Bayar NG 51988 Lave Germany (	Wed Mer.	Wed Mer.	Mandactured by IF da Bayer AG 5008 Laverkusen Germany / Alemagne	Wed Mer.	Wed Mer.	Mandactured by IF da Bayer AG 5000 Laverusen Gerrr any i Alemagne	Wed Mer.	Wed Mer.	Mandactured by IF d Bayer AG 5008 Lavertusen Gerrany (Allemagne	Wed Mer.	Wed Mer.	Manufactured by (Fid) Bayer AG 5008 Lavenuen Gern any ( Alemagne	Wed Mer.	Wed Mer.	lil andactured by 1F do Bayer AG 5088 Lavekusen Germany (Alemagne	Wed Mer.
Thu Jeu.		Thu Jeu.	Thu Jeu.	se Politica	Thu Jeu.	Thu Jeu.		Thu Jeu.	Thu Jeu.		Thu Jeu.	Thu Jeu.		Thu Jeu.	Thu Jeu.		Thu Jeu.
Fri Ven.	5 mg Tal se Comprim oraté	Fri Ven.	Fri Ven.	5 mg Tal se (Comprim oraté	Fri Ven.	Fri Ven.	5 mg Tal se/Comprim to rate	Fri Ven.	Fri Ven.	5 mg Tal te (Comprim oraté	Fri Ven.	Fri Ven.	5 mg Tal es/Comprim oraté	Fri Ven.	Fri Ven.	5 mg Tal se Comprim to rate	Fri Ven.
Sat Sam.	Xarelto*2.5 mg Tablets Fn constitutes Comprise Maules Riversontum Carlue / Yole onde	Sat Sam.	Sat Sam.	Xarelto*2.5 mg Tablets An countrates / Contrine Peeules Revension Crause / Vole code	Sat Sam.	Sat Sam.	Xarelto*2.5 mg Tablets Fin countrates Commercentules Reconstrum Grad the / Yole onde	Sat Sam.	Sat Sam.	Xarelto*2.5 mg Tablets Proceedrates (continue Petules Reveoxation Carlue / Vole orde	Sat Sam.	Sat Sam.	Xarelto*2.5 mg Tablets An coad Table (Corprise Reuse Reconstan Gal Use / Vole onde	Sat Sam.	Sat Sam.	Xarelto*2.5 mg Tablets An coerditates Commercedules Remonstern Carl los / Yole onde	Sat Sam.
Sun Dim. #7058646	MFD EXP	Sun Dim.	Sun Dim. 87058646	MFD	Sun Dim.	Sun Dim. 87058646	MFD	Sun Dim.	Sun Dim.	MFD	Sun Dim.	Sun Dim.	MFD	Sun Dim.	Sun Dim.	MFD	Sun Dim.
Mon	LOT	87058646		LOT	87058646		LOT	87058646 Mon	Mon	LOT	a7058646 Mon	Mon	LOT	87058646		LOT	ATOSA646 Mon
Lun.	riqué par	Mon Lun.	Mon Lun.	riqué par	Mon Lun.	Mon Lun.	riqué par	Lun.	Lun.	riqué par:	Lun.	Lun.	liqué par	Mon Lun.	Mon Lun.	riqué par	Lun.
Tue Mar.	Man utholured by / Fabriq Bayer / G 5588 Loverhuson Germany / Misnagne	Tue Mar.	Tue Mar.	Man ubstared by Friantysk p.ar. 18.ger AG 5080 Lovehuaen Germany ( Managne	Tue Mar.	Tue Mar.	Man uthchured by Frianigal p.ar. Baux XG 51981 Leverhunen Germany F.M.eragne	Tue Mar.	Tue Mar.	Man utactured by / Fabriq Bayer AG 50301.Lovehuaen Gerrany / Mertagne	Tue Mar.	Tue Mar.	Manutactured by/Fathiqué par Baye XG 51081Leverturen Cermany / Martagne	Tue Mar.	Tue Mar.	Manutactured by / Fabriqué par: Bayer AG 5088 Loverhuten Gerrany / Martagne	Tue Mar.
Wed Mer.	Man uthoth Bayer AG 512881 Levu Germany i	Wed Mer.	Wed Mer.	Manufach Bayer AG 51081 Jav	Wed Mer.	Wed Mer.	Man uffects Bayer AG 51083 Levr	Wed Mer.	Wed Mer.	Manufach Bayer AG 512081 Lev	Wed Mer.	Wed Mer.	Man uthoft Bayer AG S1081 Lev	Wed Mer.	Wed Mer.	Manufach Bayer AG 51368 Levr	Wed Mer.
Thu Jeu.		Thu Jeu.	Thu Jeu.	slets	Thu Jeu.	Thu Jeu.		Thu Jeu.	Thu Jeu.		Thu Jeu.	Thu Jeu.	elets	Thu Jeu.	Thu Jeu.	e Peters	Thu Jeu.
Fri Ven.	.5mg Tak derComprin des Comprin	Fri Ven.	Fri Ven.	.5mg Tat ds/Corprin e asl6	Fri Ven.	Fri Ven.	.5mg Tat Ids/Compris e calé	Fri Ven.	Fri Ven.	.5mg Tat ds/Comprim ds/Comprim	Fri Ven.	Fri Ven.	.5mg Tak Ids/Conprin or at b	Fri Ven.	Fri Ven.	.5mg Tat ds/Corprin o call	Fri Ven.
Sat Sam.	Xarehto*2.5mg Tablets Fh.Carofiadasi Corprise Madas Riarcanahan Orat Lao / Valo ank	Sat Sam.	Sat Sam.	Xaretto*25mg Tablets Fin Caraottades (Compres Maduk Riameatam Ord Use /Vale calls	Sat Sam.	Sat Sam.	Xaretto*25mg Tablets Fin.carafads: Congrins Pataus Riarreatan Oral Use / Vale caris	Sat Sam.	Sat Sam.	Xarelto*25mg Tablets Fin carotades (Continue Pelades Riareatan Ond Use /Vde cate	Sat Sam.	Sat Sam.	Karelto*2.5mg Tablets Fin.cororTatsi Conprise Naturals Riverseatum Ord Use /Vide corb	Sat Sam.	Sat Sam.	Xarehto*25mg Tablets FH-Core Tablet Corprise Reades Riarceatum Ord Lue / Vide ank	Sat Sam.
Sun Dim. 87058646	MFD EXP	Sun Dim.	Sun Dim. #7058646	MFD EXP	Sun Dim.	Sun Dim. 87058646	MFD EXP	Sun Dim.	Sun Dim. 87058646	MFD EXP	Sun Dim.	Sun Dim. 87058646	MFD EXP	Sun Dim.	Sun Dim.	MFD EXP	Sun Dim.

Secondary pack label;

